Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1995-2-8
|
| pubmed:abstractText |
Anthracycline antibiotics represent a part of therapeutic schemes in the treatment of a wide spectrum of malignancies. Precisely due to their cytostatic effectiveness they are being applied in spite of the risk of cardiac damage of patients. Anthracycline cardiotoxicity may culminate in potentially irreversible heart failure and fatal arrhythmias. Consequences of cardiotoxicity can complicate and shorten the lives of patients with formerly favourable prognosis of the malignant disease, and even of those that have been cured.
|
| pubmed:language |
slo
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0006-9248
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
95
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
304-22
|
| pubmed:dateRevised |
2009-11-11
|
| pubmed:meshHeading | |
| pubmed:year |
1994
|
| pubmed:articleTitle |
[Pathogenesis, prevention and detection of cardiotoxicity of anthracycline cytostatic agents].
|
| pubmed:affiliation |
Ustav patologickej fyziológie LFUK v Bratislave, Slovakia.
|
| pubmed:publicationType |
Journal Article,
English Abstract,
Review
|